To identify pathogenic mutations in the guanylate cyclase-activating protein 1 (GCAP1) and GCAP2 genes and to characterize the biochemical effect of mutation on guanylate cyclase (GC) stimulation. METHODS. The GCAP1 and GCAP2 genes were screened by direct sequencing for mutations in 216 patients and 421 patients, respectively, with various hereditary retinal diseases. A mutation in GCAP1 segregating with autosomal dominant cone degeneration was further evaluated biochemically by employing recombinant proteins, immunoblotting, Ca 2ϩ -dependent stimulation of GC, fluorescence emission spectra, and limited proteolysis in the absence and presence of Ca 2ϩ .
RESULTS.
A novel GCAP1 mutation, I143NT (substitution of Ile at codon 143 by Asn and Thr), affecting the EF4 Ca 2ϩ -binding loop, was identified in a heterozygote father and son with autosomal dominant cone degeneration. Both patients had much greater loss of cone function versus rod function; previous histopathologic evaluation of the father's eyes at autopsy (age 75 years) showed no foveal cones but a few, scattered cones remaining in the peripheral retina. Biochemical analysis showed that the GCAP1-I143NT mutant adopted a conformation susceptible to proteolysis, and the mutant inhibited GC only partially at high Ca 2ϩ concentrations. Individual patients with atypical or recessive retinitis pigmentosa (RP) had additional heterozygous GCAP1-T114I and GCAP2 gene changes (V85M and F150C) of unknown pathogenicity. CONCLUSIONS. A novel GCAP1 mutation, I143NT, caused a form of autosomal dominant cone degeneration that destroys foveal cones by mid-life but spares some cones in the peripheral retina up to 75 years. Properties of the GCAP1-I143NT mutant protein suggested that it is incompletely inactivated by high Ca 2ϩ concentrations as should occur with dark adaptation. The continued activity of the mutant GCAP1 likely results in higherthan-normal scotopic cGMP levels which may, in turn, account for the progressive loss of cones. R od and cone phototransduction cascades rapidly activate a cGMP phosphodiesterase when rhodopsin is photoactivated. The final steps of the phototransduction cascade are a reduction of cytoplasmic cGMP and the closure of cGMP-gated cation channels in the plasma membrane. 1 To recover from a photoresponse, cGMP must be replenished by photoreceptor guanylate cyclases (GCs). When the level of cGMP (1-10 M) is replenished, cGMP-gated channels reopen, and dark-adapted Ca 2ϩ levels (600 -1000 nM) are restored. Activity of the photoreceptor GC is regulated via retina-specific guanylate cyclaseactivating proteins, or GCAPs. In the dark, when the intracellular Ca 2ϩ level is relatively high due to its continuous influx through open channels, Ca 2ϩ -bound GCAPs are inactive. In the light, the closed channels result in reduced Ca 2ϩ levels, thereby allowing the Ca 2ϩ ions to dissociate from the GCAPs. Ca 2ϩ -free GCAPs are then able to stimulate GC, resulting in an acceleration of cGMP synthesis. Disruption of these events by mutations in genes encoding PDE subunits, 2-4 GC1, 5, 6 GCAP1, [7] [8] [9] and the subunits of the rod and cone cGMP-gated channels, 10 -15 cause photoreceptor degenerations such as retinitis pigmentosa, Leber congenital amaurosis, cone dystrophy, or congenital stationary night blindness. 16, 17 Multiple GCAP gene duplications have taken place during evolution. Up to eight GCAPs (GCAP1 to -8) have been identified in teleosts. 18 In the mammalian retina, only three GCAP isoforms (GCAP1 to -3) are expressed. 19 In humans, GCAP1 and GCAP2 are encoded by a tail-to-tail gene array on chromosome 6p 20 while the GCAP3 gene is located on chromosome 3q. 21 All three GCAPs are expressed in rods and cones, 19 but mutations in only the GCAP1 gene have been associated with human retinal disease, namely, autosomal dominant cone dystrophy (adCD). Cone-specific degenerations due to GCAP1 defects are consistent with the high levels of GCAP1 in the outer segments of this cell type. One reported mutation (Y99C) results in a Tyr to Cys change in EF3. 22, 23 Another mutation, E155G, 9 replacing the last acidic residue of the EF hand with a neutral residue, is predicted to affect Ca 2ϩ coordination at EF4. Acidic Glu/Asp residues, occupying the first and last positions of the loop, are required for effective Ca 2ϩ coordination. 24 E155 is 100% conserved in all GCAPs sequenced so far, suggesting that this residue is essential. A third reportedly pathogenic mutation (GCAP1-P50L) found in one family with cone-rod dystrophy 25 causes disease by an entirely different mechanism 26 or may be a nonpathogenic rare variant. No disease-causing mutations have yet been reported in the human GCAP2 27 and GCAP3 genes.
This contribution describes our recent searches for mutations in the GCAP1 and GCAP2 genes among patients with hereditary retinal diseases. Analysis of the GCAP1 gene was focused on patients whose disease included cone dysfunction or degeneration as a prominent feature. Analysis of the GCAP2 gene included patients with rod and cone dysfunction or degeneration, since this gene is thought to be expressed in both photoreceptor cell types.
28,29

MATERIALS AND METHODS
Ascertainment of Patients and Controls
This study conformed to the tenets of the Declaration of Helsinki and was approved by Internal Review Boards at the Massachusetts Eye and Ear Infirmary and Harvard Medical School. Almost all patients were recruited from the Berman-Gund Laboratory and were diagnosed with a hereditary retinal disease after an eye examination that included an electroretinogram (ERG). Patients with cone-rod degeneration had a substantially more severe reduction in cone versus rod ERG amplitudes. Patients with retinitis pigmentosa had more severe reduction in rod versus cone ERG amplitudes or had comparable reductions in rod and cone amplitudes. Patients with achromatopsia had absent color vision and severely reduced cone ERGs and normal to slightly subnormal rod ERGs from early childhood. Patients with cone degeneration had reduced central visual acuity, a reduction in cone ERGs, and normal or slightly subnormal rod ERGs. Patients with cone dysfunction had some but not all clinical features diagnostic of cone degeneration or achromatopsia. Control individuals had no symptoms of hereditary retinal disease and had no known blood relatives with such diseases.
ERGs were recorded after maximal dilation of the pupil and at least 40 minutes of dark-adaptation. 30 -32 Blood samples were obtained from the patients. Relatives of some patients were also recruited for this study and donated blood samples. Control blood samples were also obtained from individuals without symptoms of or family history of retinal disease. Leukocyte DNA was purified using standard procedures.
Mutation Screening
The open reading frames of the GCAP1 and GCAP2 genes, including their flanking intron splice sites, were amplified using the polymerase chain reaction and the primers listed in Table 1 . The DNA sequences were obtained by direct DNA sequencing using a dye-terminator cycle sequencing kit (version 3.1; Applied Biosystems, Foster City, CA) and an automated sequencer (ABI model 3100; Applied Biosystems). The numbering of the codons of the cDNA of GCAP1 and GCAP2 in this article are according to GenBank accession numbers L36859 and NM-002098, respectively 20, 33 ; NT-007592 was used for the numbering of the genomic sequence for both genes (GCAP1 and GCAP2 genes are separated by 5420 bp).
Expression Constructs of Mutant GCAPs
The mutations were introduced into a human GCAP1 plasmid (hG-CAP1) by site-directed mutagenesis, 33 and the mutant GCAPs were expressed in insect cells. Briefly, the EcoRI-digested insert of hGCAP1 was cloned into pFastBac-1, and transformed into XL1-Gold Escherichia coli strain. The orientation of the resulting plasmid was confirmed with Pst1 digests and the mutations were verified by DNA sequencing with the primers 5Ј-GTTGGCTACGTATACTCCGG and 5Ј-GTAAAACCTCTACAAATGTGG. Mutagenesis to generate GCAP1-I143NT was carried out in this plasmid using the sense primer 5Ј-CAGTGTTCTCCAAGAATACCGACGTCAACGGGGAT and the antisense primer 5Ј-ATCCCCGTTGACGTCGGTATTCTTGGAGAACACTG. Mutagenesis to generate GCAP1-E155G 9 as an internal control was carried out with the sense primer 5Ј-AACTCTCCCTGGAAGGGTT-TATAGAGGGCGT and the anti-sense primer 5Ј-ACGCCCTCTATAAAC-CCTTCCAGGGAGAGTT. Wild-type human GCAP1, GCAP1-E155G, and GCAP1-I143NT pFastBac plasmids were transformed into DH10Bac E. coli to generate the recombinant bacmid DNAs (Bac-to-Bac Baculovirus Expression System, Invitrogen, Carlsbad, CA). The bacmids were transfected into High five insect cells (Invitrogen) to produce recombinant baculovirus and proteins.
SDS PAGE and Western Blot Analysis
The expression of GCAP1 proteins was confirmed with UW101 antibody using SDS PAGE and Western blot analysis as described. 34 All purification procedures were performed at 4°C. After homogenization, cell suspensions were centrifuged at 100,000g for 20 minutes. Again, all purification procedures were carried out at 4°C. Supernatants were used as a source of recombinant proteins for protein purification. GCAPs were purified using monoclonal antibody (G2) coupled to CNBr-activated Sepharose resin (ϳ5 mg IgG/1 mL gel) as described previously. 35 Purified proteins were dialyzed overnight against 10 mM Bis-Tris Propane (1,3-bis(tris[hy- , and limited proteolysis of purified GCAP1 and GCAP1 mutants, were carried out as described previously.
36
GC Activity Assay
Washed rod outer segment (ROS) membranes 37 were prepared from fresh bovine retinas reconstituted with recombinant GCAPs and assayed as described. 38 [Ca 2ϩ ] was calculated using the computer program Chelator 1.00 39 and adjusted to higher concentrations by increasing the amount of CaCl 2 . All assays were repeated at least twice.
Fluorescence Measurements
Fluorescence measurements of GCAP1 and its mutants were carried out on a spectrofluorimeter (LS 50B; Perkin-Elmer, Boston, MA) using a 1 ϫ 1-cm quartz cuvette. Emission spectra were recorded with excitation at 280 nm at 5 nm slit widths. Spectra were determined in 50 mM HEPES (pH 7.8), containing 60 mM KCl, 20 mM NaCl, 1 mM EGTA, 1 mM dithiothreitol, and 4.6ϫ10 Ϫ8 to 2.4ϫ10 Ϫ6 M CaCl 2 .
RESULTS AND DISCUSSION
GCAP1 Gene Mutations
The GCAP1 gene was analyzed in 216 patients with cone degeneration, cone-rod degeneration, achromatopsia, or other hereditary retinal disease in which cones degenerate or are dysfunctional (Table 2) . Five DNA sequence changes were found in a total of six patients (Table 3) . One of the changes, I143NT (c.428delTinsACAC), affected a residue in the ␣-helix immediately flanking the Ca 2ϩ -binding site (EF4). This change 
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was found in an index patient with autosomal dominant cone degeneration, and it was not found among 93 control individuals. The index patient IV-1 (family #3761) and his affected son V-1 were both heterozygous for this change; the one unaffected relative (a daughter, V-2) who was analyzed did not carry the change (Fig. 1) . A missense change, T114I (c.341CϾT), was identified in another index patient, also a heterozygote, with an atypical form of retinal degeneration (Fig. 1A) . The patient had no known affected relatives, and the few living unaffected relatives could not be located. Thus we could not determine whether they also carried this change. At age 29 years, the patient had rod ERG amplitudes reduced approximately 70%-75% below the lower limit of normal, and cone ERG amplitudes reduced only approximately 65% below the lower limit of normal (Fig. 1B) . This reduction in rod and cone ERG amplitudes was very different from that found in previously reported patients with GCAP1 mutations and was different from our patient with the GCAP1-I143NT mutation.
Three other novel GCAP1 changes were found in one or two patients each, all heterozygotes, and were interpreted as likely nonpathogenic rare variants: an A-to-G transition in the 5Ј-untranslated region, a 1-bp deletion in intron 3, and an isocoding change in codon D189 (Table 3) . None of these three changes is predicted to affect the amino acid sequence of the encoded protein. None of these three changes, and neither the I143NT nor the T114I change, appears to create or destroy any splice donor or acceptor site, based on analysis with splice-site prediction software (available at http://www. fruitfly.org/seq_tools/splice.html).
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Ocular Findings of Patients with GCAP1-I143NT
The ocular findings and ERGs of the affected father and son from this family with the GCAP1-I143NT mutation have been previously reported. 41 Although the son at age 15 years had visual acuity of 20/20 in both eyes, his cone function was severely compromised, as indicated by his absent color vision (i.e., his inability to arrange the Farnsworth D-15 panel or to correctly identify Hardy-Rand-Rittler (HRR) color plates). The father at age 45 had photophobia, visual acuity of 20/300 in both eyes, absent color vision, and small regions of retinal atrophy in the center of the macula of both eyes. ERGs of both the father at age 45 and the son at age 25 showed minimal if any 30-Hz cone ERG responses and intact 0.5-Hz rod ERG responses to blue or white light (Fig. 1B) . 41 Early receptor potential amplitudes after a bleaching light recovered at a rate slower than normal and corresponded to the normal rate of rhodopsin regeneration, indicating little to no cone function. 42, 43 The eyes of the father, obtained at autopsy at age 75, revealed the absence of rod and cone photoreceptors in the central macula; some degenerating photoreceptor inner and outer segments were seen in the parafoveal region. 44 In the periphery, the rod photoreceptors were intact and normal in number, and a few intact cone photoreceptors were also present.
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GCAP2 Gene Mutations
The GCAP2 gene was analyzed in 190 patients with autosomal dominant retinitis pigmentosa, 93 with autosomal recessive retinitis pigmentosa, and 138 patients with various forms of retinal degeneration/dysfunction ( Table 2) . Five rare variants were identified in a total of six heterozygous patients ( Table 4) . Two of them were missense changes, both affecting residues in ␣-helices flanking the Ca 2ϩ -binding domain. A V85M mutation was found in a heterozygote patient with atypical retinal degeneration with no family history. An F150C change was found in a heterozygous patient with recessive RP who was the offspring of a consanguineous marriage. No likely mutation affecting the other allele was identified in either patient. The remaining three rare variants were isocoding or intron changes predicted not to affect the encoded protein (Table 4) . Six DNA sequence changes were found that were interpreted as nonpathogenic polymorphisms because they were found in Ͼ1% of alleles (Table 4) . One of the polymorphisms is a previously reported 27 missense alteration (E155D) that affects the last residue in the highly conserved Ca 2ϩ -binding domain EF3. However, this mutation was previously also found in a normal control. 27 Splice-site prediction software found no evidence that any of the GCAP2 changes created or destroyed RNA splice sites.
Biochemical Analysis of the GCAP1-I143NT Mutant
Although the GCAP1-I143NT mutation cosegregated with cone degeneration in family #3761, the available family members were few in number and the cosegregation of the mutation with the disease could have been by chance. Further evidence for the pathogenicity of this mutation, however, came from analyses of the ability of the mutant recombinant protein to stimulate GC as a function of [Ca 2ϩ ]. The residue Ile143 precedes the EF4 loop in GCAP1 (Fig.  2A) . This position, typically occupied by a hydrophobic residue, is invariant in the EF4 hand motifs of GCAP1 ( Fig. 2A) , and in the closely related GCAP2 and GCAP3 sequences (not shown). To test the presumed importance of this residue for Ca 2ϩ binding, human GCAP1, the mutant GCAP1-I143NT, and the mutant GCAP1-E155G which had earlier been shown to be associated with cone dystrophy, 9 were expressed in insect cells. When the affinity-purified proteins were analyzed by SDS PAGE (Fig. 2C) in the presence of high Ca 2ϩ (1 mM) and in the absence of Ca 2ϩ (1 mM EGTA), normal and mutant GCAP1s exhibited a change in mobility ("Ca 2ϩ -shift"). This mobility shift is typical for calmodulin-like Ca 2ϩ -binding proteins and indicated a large rearrangement of the 3D structure from an open form (Ca 2ϩ -free, the slower moving active form) to a more compact Ca 2ϩ -bound conformation (the faster moving inactive form). The Ca 2ϩ -shift was somewhat smaller in the mutant proteins, consistent with impaired Ca 2ϩ binding to EF4.
Persistent Stimulation of Photoreceptor GC by GCAP1-I143NT
We next assayed the degree to which mutant GCAP1-I143NT stimulated GC as a function of [Ca 2ϩ ]. We expected incomplete inactivation of GC1 at the high Ca 2ϩ levels found in dark-adapted photoreceptors, similar to what has been reported for GCAP1-Y99C 22, 23 and GCAP1-E155G. 9 As shown in Figure 2B , GCAP1-I143NT was active at low Ca 2ϩ (Ͻ200 nM), as was wild-type GCAP1, but the mutant remained active (30%-50%) even at high dark [Ca 2ϩ ] free -levels (ϳ700 nM) when wild-type GCAP1 was inhibited. Similar incomplete suppression of GC activity was previously found with a GCAP1-Y99C mutation affecting EF3. 23 The mutant GCAP1-E155G exhibited similar incomplete suppression of GC activity, suggesting that in both mutants, as evidenced by the rightward shift in the Ca 2ϩ -titration curve, EF4 binds Ca 2ϩ with an impaired affinity. This conclusion is consistent with our previous finding that the GCAP1-E155D 36 mutant, which is not able to bind Ca 2ϩ to this loop, showed activity even at high, nonphysiological Ca 2ϩ levels (50 M [Ca 2ϩ ] free ). Mutagenesis experiments showed that when both EF3 and EF4 of GCAP1 are defective and allow no Ca 2ϩ binding, GCAP1 was converted into a Ca 2ϩ -insensitive GC stimulator (Fig. 6B in Ref.36) . Taken together, the findings indicate that Ca 2ϩ binding by EF3 and EF4 is critical for inactivation of GCAP1, and dissociation of Ca 2ϩ from these sites converts GCAP1 from the inactive to an active state. Mutations affecting only one of these sites will partially impair GC inhibition, leading to persistent stimulation in dark-adapted photoreceptors.
Fluorescence Emission Spectra of GCAP1 Mutants
A sensitive assay for changes in Ca 2ϩ -binding is to measure intrinsic Trp fluorescence. Trp21 in the N-terminal domain, Trp51 between EF1 and EF4, and Trp94 near EF3 can be used to monitor changes in conformation when excited with UV light 45 ( Fig. 3 ). An increase of Ca 2ϩ bound to GCAP1 caused a decrease in fluorescence intensity with a minimum occurring at 200 -300 nM [Ca 2ϩ ] free (Fig. 3A) . Further increases in Ca 2ϩ levels reversed this trend and caused an increase in fluorescence intensity (Fig. 3A) . These changes in the fluorescence correlated with a structural rearrangement of GCAP1 and a transition from an activator to an inhibitor of photoreceptor GC. However, when the GCAP1 mutants were analyzed, we noticed a significantly modified dependence of fluorescence intensity on Ca 2ϩ levels: high Ca 2ϩ levels did not increase the fluorescence of the mutant proteins (Figs. 3B and 3C ) apart from a small shoulder at 300 -600 nM [Ca 2ϩ ] free . Since Trp residues were not present only in the Ca 2ϩ -binding sites, the fluorescence data provided general information about structural changes in GCAP1, unrelated to specific regions such as EF4.
GCAP1 Structure and the Consequence of I143NT Mutation
The four EF hands of GCAP1 are arranged in pairs that gave rise to N-and C-terminal domains which form a relatively compact structure (Fig. 4) . Three Ca 2ϩ ions are bound to GCAP1 at EF2, EF3, and EF4, as predicted on the basis of its amino acid sequence and by numerous site-directed mutagenesis experiments. 23, 36, 38, [45] [46] [47] EF1 does not bind Ca 2ϩ because the binding loop is distorted by a Pro at the fourth position of the 12 residue loop. In addition, the preceding residue (Cys) is not suitable for the coordination of Ca 2ϩ ions. Modeling of EF4 of GCAP1, based on the recoverin crystal structure, 48 and the structure of GCAP2, revealed through nuclear magnetic resonance techniques, 49 suggests that substitution of Ile143, positioned at the N-terminal end of EF4, by two polar residues will change the orientation of the N-terminal ␣-helix, distorting the loop conformation that is essential for Ca 2ϩ binding, and decreasing the affinity for Ca 2ϩ (Figs. 4A and 4B ). Changes in these positions among other Ca 2ϩ -binding proteins have also been shown to impair Ca 2ϩ coordination. 24 The effect of the mutation on the structure of GCAP1 can be monitored by subjecting GCAP1 and GCAP1-I143NT to limited proteolysis (Fig. 4C) . In the absence of Ca 2ϩ , GCAP1 assumed an open conformation and was readily digested by trypsin (last lane, both gels). In the presence of Ca 2ϩ , GCAP1 assumed a compact structure, and proteolysis was restricted. Under the same conditions, GCAP1-I143NT, in which Ca 2ϩ -binding is impeded at EF4, was more susceptible to proteolysis. Thr114 (Table 3) , a residue which was mutated to Ile in family 6551 (Fig. 1A) , was located on the C-terminal helix of EF3 (Fig. 4) . Substitution at this conserved region among GCAPs 18, 19 may also affect coordination of Ca 2ϩ to this loop, consistent with the GCAP1-Y99C mutant affecting Ca 2ϩ binding in EF3, or it may modify the interaction with GCs. Since the patient with the GCAP1-T114I changes had no family history of retinal disease and since his retinal disease was very different from that found in other patients with GCAP1 mutations, this mutant was not further biochemically characterized.
CONCLUSIONS
In summary, GCAP1-I143NT stimulated photoreceptor GC effectively at low [Ca 2ϩ ] free , to a degree comparable to wild-type GCAP1 and the GCAP1-E155G mutant. However, the Ca 2ϩ -sensitivity of the GCAP1 mutants was markedly altered, causing persistent stimulation of GC when exposed to high Ca 2ϩ levels such as those present in dark-adapted photoreceptors. This activity is consistent with the dominant phenotype produced by the mutant alleles causing cone degeneration. Persistent stimulation of GC by the mutant proteins is predicted to lead to elevated levels of cGMP in the dark-adapted retina, which in turn causes a higher FIGURE 4. Model of GCAP1 and distortion of EF4 by insertion of two residues. (A) The model of GCAP1 is based on the NMR structure of GCAP2 (as deposited in the Protein Data Bank, PDB ID# 1JBA). 50 The Nterminal domain is in blue, the Cterminal domain is in red, and the central helix is in yellow. Ca 2ϩ ions are shown in blue, and the side chains of the residues Ile143 and Thr114 are shown with the van der Waals spheres. (B) A cartoon of EF4 depicting how the replacement of hydrophobic Ile143 by two polar residues may lower affinity for Ca 2ϩ . (C) Limited proteolysis of GCAP1 and GCAP1-I143NT by trypsin. The digestion was carried out at 30°C at a ratio of GCAP1/trypsin 300:1, and the digest was analyzed by SDS-PAGE at 0, percentage of cGMP-gated channels in the plasma membrane to be open. It is likely that the actual cGMP level in the dark-adapted photoreceptors will be a balance between the excessive production of cGMP by GC stimulated by the mutant GCAP1 and hydrolysis of cGMP through the basal activity of PDE. The altered physiological cGMP levels may be subtle and thus cause a relatively slow retinal degeneration. The reason for the mostly conespecific degeneration in response to this physiological defect may be because GCAP1 may be more active in cones than rods, or, alternatively, it may reflect other differences in cGMP metabolism between rods and cones. It remains unexplained why some cones in the peripheral retina 44 can survive for over 70 years, while rods and cones in the fovea and perifovea degenerate. Since the abnormality of photoreceptor physiology in the affected patients would be expected to occur mainly in darkness or dim light (persistent GC stimulation in the dark), it is doubtful that reducing light exposure (such as by wearing sunglasses) would slow their rate of progressive visual loss. Whether reducing exposure to darkness (such as by keeping lights on at night while sleeping) would be helpful is uncertain. Animal models with homologous dominant GCAP1 mutations might be helpful to address this uncertainty.
